Diagnostic performance in active TB of QFT-Plus assay and co-expression of CD25/CD134 in response to new antigens of Mycobacterium tuberculosis

Medical Microbiology and Immunology

Volumn 208, Issue 2, 2019, Pages 171-183

  Sauzullo, Ilaria ^a   Mengoni, Fabio ^a   Mascia, Claudia ^a   Pavone, Paolo ^a   Savelloni, Giulia ^a   Massetti, Anna Paola ^a   Lichtner, Miriam ^a,b   Vullo, Vincenzo ^a   Mastroianni, Claudio M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

CD25 CD134; Flow cytometry; QFT Plus; Tuberculosis

Indexed keywords

CD134 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; BACTERIAL ANTIGEN; IL2RA PROTEIN, HUMAN; TNFRSF4 PROTEIN, HUMAN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; EVALUATION STUDY; IMMUNOLOGY; INTERFERON GAMMA RELEASE ASSAY; MIDDLE AGED; PROCEDURES; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

ADULT; ANTIGENS, BACTERIAL; FEMALE; HUMANS; INTERFERON-GAMMA RELEASE TESTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; RECEPTORS, OX40; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

EID: 85059749890     PISSN: 03008584     EISSN: 14321831     Source Type: Journal    
DOI: 10.1007/s00430-018-00576-4     Document Type: Article

References (42)

1. WHO (2017) Global Tuberculosis Report 2017. World Health Organization, Geneva. http://www.who.int/tb/publications/global_report/en/. Accessed 3 July 2017
2. Fry DE (2016) Extra-pulmonary tuberculosis and its surgical treatment. Surg Infect 17:394–401
3. Ali Chaudhry L, Al-Solaiman S (2013) Multifocal tuberculosis: many faces of an old menace. Int J Mycobacteriol 2:58–69
4. Tyagi S, Sharma N, Tyagi JS, Haldar S (2017) Challenges in pleural tuberculosis diagnosis: existing reference standards and nucleic acid tests. Future Microbiol 12:1201–1218. 10.2217/fmb-2017-0028
5. Whitworth HS, Scott M, Connell DW, Dongés B, Lalvani A (2013) IGRAs—the gateway to T cell based TB diagnosis. Methods 61:52–62
6. Andersen P, Munk ME, Pollock JM, Doherty TM (2000) Specific immune-based diagnosis of tuberculosis. Lancet 356:1099–1104
7. QuantiFERON®-TB Gold Plus (QFT®-Plus) ELISA Package Insert. QUIAGEN http://www.quantiferon.com/irm/content/PI/QFT/PLUS/2PK-Elisa/UK.pdf. Accessed 7 Oct 2017
8. Zaunders JJ, Munier ML, Seddiki N, Pett S, Ip S, Bailey M et al (2009) High levels of human antigen-specific CD4 + T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J Immunol 183:2827–2836. 10.4049/jimmunol.0803548
9. Metcalfe JZ, Cattamanchi A, McCulloch CE, Lew JD, Ha NP, Graviss EA (2013) Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice. Am J Respir Crit Care Med 187:206–211. 10.1164/rccm.201203-0430OC
10. Barcellini L, Borroni E, Brown J, Brunetti E, Campisi D, Castellotti PF et al (2016) First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. Eur Respir J 48:1411–1419. 10.1183/13993003.00510-2016
11. Chen X, Zhou B, Li M, Deng Q, Wu X, Le X et al (2007) CD4 + CD25 + FoxP3 + regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. Clin Immunol 123:50–59
12. Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P et al (2005) Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 172:631–635
13. Kim K, Perera R, Tan DBA, Fernandez S, Seddiki N, Waring, French MA (2014) Circulating mycobacterial-reactive CD4 + T cells with an immunosuppressive phenotype are higher in active tuberculosis than latent tuberculosis infection. Tuberculosis 94:450–494
14. Serbina NV, Lazarevic V, Flynn JL (2001) CD4 (+) T cells are required for the development of cytotoxic CD8(+) T cells during Mycobacterium tuberculosis infection. J Immunol 167:6991–7000
15. Hogan C, Tien S, Pai M, Banaei N (2018) Higher positivity rate with 4th generation QuantiFERON-TB Gold Plus assay in low-risk U.S. healthcare workers. J Clin Microbiol. 10.1128/JCM.01688-18
16. Hoffmann H, Avsar K, Gores R, Mavi SC, Hofmann-Thiel S (2016) Equal sensitivity of the new generation QuantiFERON-TB Gold Plus in direct comparison with the previous test version QuantiFERON-TB Gold IT. Clin Microbiol Infect 22:701–703. 10.1016/j.cmi.2016.05.006. (Epub 2016 May 13)
17. Moon HW, Gaur RL, Tien SS, Spangler M, Pai M, Banaei N (2017) Evaluation of QuantiFERON-TB Gold-Plus in health care workers in a low incidence setting. J Clin Microbiol 55:1650 – 1657. 10.1128/JCM.02498-16
18. Telisinghe L, Amofa-Sekyi M, Maluzi K, Kaluba-Milimo D, Cheeba-Lengwe M, Chiwele K et al (2017) The sensitivity of the QuantiFERON-TB Gold Plus assay in Zambian adults with active tuberculosis. Int J Tuberc Lung Dis 21:690–696. 10.5588/ijtld.16.0764
19. Takasaki J, Manabe T, Morino E, Muto Y, Hashimoto M, Iikura M et al (2018) Sensitivity and specificity of QuantiFERON-TB Gold Plus compared with QuantiFERON-TB Gold In-Tube and T-SPOT.TB on active tuberculosis in Japan. J Infect Chemother 24:188 – 192. 10.1016/j.jiac.2017.10.009
20. Theel ES, Hilgart H, Breen-Lyles M, McCoy K, Flury R, Breeher LE et al (2018) Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube interferon gamma release assays in patients at risk for tuberculosis and in health care workers. J Clin Microbiol 56:e00614–e00618. 10.1128/JCM.00614-18
21. Petruccioli E, Vanini V, Chiacchio T, Cuzzi G, Cirillo DM, Palmieri F et al (2017) Analytical evaluation of QuantiFERON-Plus and QuantiFERON-Gold In-tube assays in subjects with or without tuberculosis. Tuberculosis 106:38–43. 10.1016/j.tube.2017.06.002
22. Nicol MP, Sola C, February B, Rastogi N, Steyn L, Wilkinson RJ (2005) Distribution of strain families of Mycobacterium tuberculosis causing pulmonary and extrapulmonary disease in hospitalized children in Cape Town, South Africa. J Clin Microbiol 43:5779–5781
23. Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, Pasvol G et al (2001) Direct ex vivo analysis of antigen specific IFN-gamma—secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 167:5217–5225
24. Jafari C, Thijsen S, Sotgiu G, Goletti D, Dominguez Benitez JA, Losi M et al (2009) Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trials group study. Am J Respir Crit Care Med 180:666–673
25. Croft M (2003) Co-stimulatory members of the TNFR family: keys to effective T cell immunity? Nat Rev Immunol 3:609–620
26. Lenardo M, Chan KM, Hornung F, McFarland H, Siegel R, Wang J, Zheng L (1999) Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Ann Rev Immunol 17:221–253
27. Petruccioli E, Chiacchio T, Pepponi I, Vanini V, Urso R, Cuzzi G et al (2016) First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus. J Infect 73:588–597. 10.1016/j.jinf.2016.09.008
28. Brookes RH, Pathan AA, McShane H, Hensmann M, Price DA, Hill AV (2003) CD8 + T cell-mediated suppression of intracellular Mycobacterium tuberculosis growth in activated human macrophages. Eur J Immunol 33:3293–3302
29. Day CL, Abrahams DA, Lerumo L, Janse van Rensburg E, Stone L, O’rie T et al (2011) Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol 187:2222–2232. 10.4049/jimmunol.1101122
30. + T cells are functionally and phenotypically different between latent infection and active disease. Eur J Immunol 43:1568–1577. 10.1002/eji.201243262
31. Rozot V, Patrizia A, Vigano S, Mazza-Stalder J, Idrizi E, Day CL et al (2015) Combined use of Mycobacterium tuberculosis-specific CD4 and CD8 T-cell responses is a powerful diagnostic tool of active tuberculosis. Clin Infec Dis 60:432–437. 10.1093/cid/ciu795
32. Lewinsohn DA, Heinzel AS, Gardner JM, Zhu L, Alderson MR, Lewinsohn DM (2003) Mycobacterium tuberculosis-specific CD8 + T cells preferentially recognize heavily infected cells. Am J Respir Crit Care Med 168:1346–1352
33. Commandeur S, van Meijgaarden KE, Prins C (2013) An unbiased genome-wide Mycobacterium tuberculosis gene expression approach to discover antigens targeted by human T cells expressed during pulmonary infection. J Immunol 190:1659–1671. 10.4049/jimmunol.1201593
34. Nyendak MR, Park B, Null MD, Baseke J, Swarbrick G, Mayanja-Kizza H et al (2013) Mycobacterium tuberculosis specific CD8(+) T cells rapidly decline with antituberculosis treatment. PLoS One 8:e81564. 10.1371/journal.pone.0081564
35. + T cells provide an immunologic signature of tuberculosis in young children. Am J Respir Crit Care Med 185:206–212. 10.1164/rccm.201107-1355OC
36. Caccamo N, Meraviglia S, La Mendola C, Guggino G, Dieli F, Salerno A (2006) Phenotypical and functional analysis of memory and effector human CD8 T cells specific for mycobacterial antigens. J Immunol 177:1780–1785
37. Dieli F, Friscia G, Di Sano C, Ivanyi J, Singh M, Spallek R et al (1999) Sequestration of T lymphocytes to body fluids in tuberculosis: reversal of anergy following chemotherapy. J Infect Dis 180:225–228
38. Hsu DC, Zaunders JJ, Plit M, Leeman C, Ip S, Iampornsin T et al (2012) A novel assay detecting recall response to Mycobacterium tuberculosis: comparison with existing assays. Tuberculosis 92:321–327. 10.1016/j.tube.2012.03.008
39. Escalante P, Peikert T, Van Keulen VP, Erskine CL, Bornhorst CL, Andrist BR et al (2015) Combinatorial immunoprofiling in latent tuberculosis infection. Toward better risk stratification. Am J Respir Crit Care Med 192:605–617. 10.1164/rccm.201412-2141OC
40. Ribeiro-Rodrigues R, Resende Co T, Rojas R, Toossi Z, Dietze R, Boom WH et al (2006) A role for CD4 + CD25 + T cells in regulation of the immune response during human tuberculosis. Clin Exp Immunol 144:25–34
41. Pennington K, Sasieta HC, Ramos GP, Erskine CL, Van Keulen VP, Peikert T, Escalante P (2017) Flow cytometric immune profiling in infliximab-associated tuberculosis. Clin Med Insights Case Rep 10:1–3. 10.1177/1179547617724776
42. Sauzullo I, Scrivo R, Sessa P, Mengoni F, Vullo V, Valesini G, Mastroianni CM (2018) Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases. Sci Rep 8:7881. 10.1038/s41598-018-26097-x